扩大抗生素、疫苗和诊断技术的研发与可及性以应对抗菌药物耐药
全球对现有抗生素无应答的细菌感染增多,需投资并确保新抗生素、疫苗和诊断技术的可及。传统依赖高收入激励的研发模式已不可持续,需公私合作等公共资助模式降低患者自付费用并提升可及性,同时重视感染预防与疫苗研发。
要点
- 传统依赖高收入激励的抗生素研发模式已不再经济可行,需推动与拉引激励并举。
- 公共资助的公私合作模式可支持抗生素及新型替代品投资,并降低患者自付费用。
- 扩大诊断技术应用面临技术、经济和行为挑战,需深入理解市场、医生和消费者行为。
核心结论
- 需投资并确保新抗生素、疫苗和诊断技术的可及性,以应对对现有抗生素无应答的细菌感染增多。
- 传统依赖高收入激励的研发模式已不再经济可行,需推动与拉引激励并举。
- 基于公私合作的公共资助模式可支持抗生素及新型替代品投资并降低患者自付费用。
主要发现
- 全球对现有抗生素无应答的细菌感染增多,表明需投资并确保新抗生素、疫苗和诊断技术的可及。
- 传统依赖高收入激励的研发模式若无推动与拉引激励,已不再经济可行。
- 通过上述机制研发的药物不太可能为所有有需要的患者所负担,尤其是低收入和中等收入国家。
- 基于公私合作的公共资助模式可支持抗生素和新型替代品的投资,并降低患者自付费用使药物更可及。
- 通过临床试验网络和平台化质量保证、生产及产品开发支持等公共产品可实现成本降低。
临床怎么用
- 保持抗生素有效性依赖于准确及时的诊断,但扩大诊断规模面临技术、经济和行为挑战。
- COVID-19大流行期间出现了新技术,但需更深入理解市场、医生和消费者行为以改善诊断在患者管理中的使用。
- 确保抗生素可持续可及还需感染预防。
- 疫苗有预防耐药病原体感染的潜力,但该背景下疫苗研发资金稀缺。
- 2024年联合国大会高级别会议为重新思考研发如何转向服务于疾病管理、预防、患者可及和抗生素管理提供了机会。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The increasing number of bacterial infections globally that do not respond to any available antibiotics indicates a need to invest in-and ensure access to-new antibiotics, vaccines, and diagnostics. The traditional model of drug development, which depends on substantial revenues to motivate investment, is no longer economically viable without push and pull incentives. Moreover, drugs developed through these mechanisms are unlikely to be affordable for all patients in need, particularly in low-income and middle-income countries. New, publicly funded models based on public-private partnerships could support investment in antibiotics and novel alternatives, and lower patients' out-of-pocket costs, making drugs more accessible. Cost reductions can be achieved with public goods, such as clinical trial networks and platform-based quality assurance, manufacturing, and product development support. Preserving antibiotic effectiveness relies on accurate and timely diagnosis; however scaling up diagnostics faces technological, economic, and behavioural challenges. New technologies appeared during the COVID-19 pandemic, but there is a need for a deeper understanding of market, physician, and consumer behaviour to improve the use of diagnostics in patient management. Ensuring sustainable access to antibiotics also requires infection prevention. Vaccines offer the potential to prevent infections from drug-resistant pathogens, but funding for vaccine development has been scarce in this context. The High-Level Meeting of the UN General Assembly in 2024 offers an opportunity to rethink how research and development can be reoriented to serve disease management, prevention, patient access, and antibiotic stewardship.
引用
- Laxminarayan R, Impalli I, Rangarajan R, et al. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance. Lancet. 2024. PMID: 38797178. doi:10.1016/S0140-6736(24)00878-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。